1H-Benzimidazole, 6-methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, potassium salt (1:1) | 161796-81-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1H-Benzimidazole, 6-methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, potassium salt (1:1)
• CAS: 161796-81-2
• 化学式: C17H19KN3O3S
• 分子量: 384.5
• InChiKey: VGDAWUJEXXBODZ-GJFSDDNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  96.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] STABLE ORAL PHARMACEUTICAL DOSAGE FORMS<br/>[FR] FORMES POSOLOGIQUES PHARMACEUTIQUES ORALES STABLES
  申请人：SAGE PHARMACEUTICALS, INC.

  公开号：WO1998050019A1

  公开（公告）日：1998-11-12

  (EN) The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage form, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.(FR) La présente invention concerne de nouvelles formes posologiques pharmaceutiques entériques stables, destinées à être utilisées par voie orale, et renfermant de l'Omeprazole ou du Lansoprazole. Cette invention concerne également une formulation et un procédé de fabrication de ces formes posologiques, ainsi qu'un procédé d'inhibition de la pompe à suc gastrique, l'utilisation de cette formulation et de ces procédés produisant un effet gastro-intestinal cytoprotecteur.

  该发明涉及用于口服的新稳定的肠溶涂层制剂，含有奥美拉唑或兰索拉唑，以及制备这种剂型的配方和方法，以及使用它们抑制胃酸泵并提供胃肠道细胞保护益处的方法。
• Solid dosage form for acid-labile active ingredient
  申请人：McNeil-PPC, Inc.

  公开号：EP1614413A2

  公开（公告）日：2006-01-11

  The present invention relates to solid, orally administrable dosage forms for acid-labile actives having at least one molded insert or core containing an acid-labile active ingredient, such as a proton pump inhibitor that is surrounded by barrier layer that is subsequently coated with an enteric layer. The present invention also relates to a dosage form that combines the barrier coated active ingredient containing insert with a second active ingredient.

  本发明涉及可口服的嗜酸活性物质固体剂型，该剂型具有至少一个含有嗜酸活性成分（如质子泵抑制剂）的模制插入物或核心，该插入物或核心被阻隔层包围，阻隔层随后涂有肠溶层。本发明还涉及一种剂型，该剂型将含有阻隔层活性成分的嵌入件与第二种活性成分结合在一起。
• PEDIATRIC SUSPENSION FORMULATION
  申请人：Xeolas Pharmaceuticals Ltd.

  公开号：EP3799861A1

  公开（公告）日：2021-04-07

  The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

  本公开涉及贮存稳定的质子泵抑制剂（PPI）系统，该系统包含治疗有效量的 PPI 或其药学上可接受的盐，如奥美拉唑或其药学上可接受的盐，在给药前用水构成。本公开还涉及口服药物混悬液，其中包括水、治疗有效量的 PPI 或其药学上可接受的盐，如奥美拉唑或其药学上可接受的盐，以及一种或多种缓冲剂。
• STABLE ORAL PHARMACEUTICAL DOSAGE FORMS
  申请人：——

  公开号：US20010006649A1

  公开（公告）日：2001-07-05

  The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

  本发明涉及含有奥美拉唑或兰索拉唑的新型稳定口服肠溶药物剂型，涉及制造这种剂型的配方和方法，还涉及使用它们抑制胃酸泵和提供胃肠道细胞保护益处的方法。
• Stable oral pharmaceutical dosage forms
  申请人：Sage Pharmaceuticals, Inc.

  公开号：US20030203018A1

  公开（公告）日：2003-10-30

  The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

  本发明涉及含有奥美拉唑或兰索拉唑的新型稳定口服肠溶药物剂型，涉及制造这种剂型的配方和方法，还涉及使用它们抑制胃酸泵和提供胃肠道细胞保护益处的方法。